Novel Antischizophrenia Treatments

1. Front Matter

   Pages i-x

   PDF

2. Clinical Instruments to Evaluate and Guide Treatment in Schizophrenia

   • Stephen R. Marder

   Pages 1-10

3. Cognitive Impairment in Schizophrenia

   • Richard S. E. Keefe, Philip D. Harvey

   Pages 11-37

4. Behavioral Animal Models to Assess Pro-cognitive Treatments for Schizophrenia

   • Jared W. Young, Nurith Amitai, Mark A. Geyer

   Pages 39-79

5. Towards Medication-Enhancement of Cognitive Interventions in Schizophrenia

   • Hsun-Hua Chou, Elizabeth Twamley, Neal R. Swerdlow

   Pages 81-111

6. Mutant Mouse Models in Evaluating Novel Approaches to Antipsychotic Treatment

   • Colm M. P. O’Tuathaigh, Lieve Desbonnet, John L. Waddington

   Pages 113-145

7. 5-HT2C Agonists as Therapeutics for the Treatment of Schizophrenia

   • Sharon Rosenzweig-Lipson, Thomas A. Comery, Karen L. Marquis, Jonathan Gross, John Dunlop

   Pages 147-165

8. The Role of Dopamine D3 Receptors in Antipsychotic Activity and Cognitive Functions

   • Gerhard Gross, Karla Drescher

   Pages 167-210

9. Nicotinic Mechanisms in the Treatment of Psychotic Disorders: A Focus on the α7 Nicotinic Receptor

   • Ann Olincy, Robert Freedman

   Pages 211-232

10. Muscarinic Mechanisms in Psychotic Disorders

    • David L. McKinzie, Frank P. Bymaster

    Pages 233-265

11. Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications

    • Joseph T. Coyle, Alo Basu, Michael Benneyworth, Darrick Balu, Glenn Konopaske

    Pages 267-295

12. Metabotropic Glutamate Receptors for New Treatments in Schizophrenia

    • E. J. Herman, M. Bubser, P. J. Conn, C. K. Jones

    Pages 297-365

13. Glycine Transport Inhibitors in the Treatment of Schizophrenia

    • Daniel C. Javitt

    Pages 367-399

14. Nicotinic Receptors and Functional Regulation of GABA Cell Microcircuitry in Bipolar Disorder and Schizophrenia

    • Francine M. Benes

    Pages 401-417

15. Development of Disease-Modifying Treatment of Schizophrenia

    • Anton Bespalov, Corinna Klein, Berthold Behl, Gerhard Gross, Hans Schoemaker

    Pages 419-442

16. Back Matter

    Pages 443-455

    PDF

This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.

• Cognition
• Neurotransmitters
• Psychopharmacology
• Schizophrenia

From the reviews:

“The target audience … is primarily researchers in the field of psychopharmacology of psychosis as well as interested psychiatrists and psychologists. … This book will provide readers with the current research issues in the psychopharmacology of schizophrenia from a ‘one disease’ perspective.” (Michael Joel Schrift, Doody's Book Reviews, March, 2013)

• Dept. Psychiatry, University of California San Diego, La Jolla, USA

  Mark A. Geyer

• Institut für Pharmakologie, Universität, Neuroscience Research, Abbott GmbH & Co. KG, Ludwigshafen, Germany

  Gerhard Gross

Policies and ethics